• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Gilead Sciences - Articles and news items

Gilead’s Phase II study showed 99% HCV cure rates

Industry news / 26 April 2017 / Niamh Marriott, Junior Editor

Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus…


Gilead on HIV: New research, new treatments and the potential for a cure

Blog, Z Homepage promo / 15 March 2017 / Mike Elliott, Vice President, Medical Affairs, Gilead Sciences

We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

EMA validates Gilead’s marketing application for their Hep C therapy

Industry news / 23 January 2017 / Niamh Marriott, Digital Editor

The application is supported by data from two Phase 3 studies, which evaluated 12 weeks of the fixed-dose combination in antiviral-experienced patients…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

PREVAIL IV – a trial to investigate if GS-5734 eliminates Ebola virus from semen

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The six-month study will enrol 60 to 120 Ebola survivors whose semen has evidence of Ebola virus RNA prior to their enrolment…

FDA approves Epclusa for treatment of chronic HCV

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection…

EC grants marketing authorisation to Odefsey in HIV

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients…

Positive CHMP opinion for Gilead’s Epclusa in HCV

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus…

EC grants marketing authorisation for two doses of Gilead’s Descovy

Industry news / 25 April 2016 / Victoria White, Digital Content Producer

Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients…

Gilead announces results from two Phase III studies of TAF in HBV

Industry news / 15 April 2016 / Victoria White, Digital Content Producer

Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection…

EMA to review Gilead’s Zydelig over safety concerns

Industry news / 14 March 2016 / Victoria White

The European Medicines Agency’s review follows concerns over serious adverse events in ongoing clinical trials of Zydelig (idelalisib)…